ISS bought by healthcare consultancy Cello Health

13 September 2019 2 min. read

Cello Health has acquired Innovative Science Solutions, a Morristown, New Jersey–based health sector consultancy.

London-based Cello Health offers research, communications, and advisory services to clients in the pharmaceutical, biotechnology, and health sectors. Its Cello Health Consulting division offers strategy consulting services to healthcare clients – with offerings ranging from early asset development and commercialization to competitor strategy. Cello Health Insight, meanwhile, focuses on market research, and has worked with every pharma company in the Global Fortune 500. Finally, Cello Health Communications creates compelling brand communications and engagement strategies to support clinical and commercial success.

The public company has US offices in New York, Philadelphia, Yardley, PA, and Florham Park, NJ, as well as European offices in London, Farnham, UK, and Berlin. Cello Health employs over 500 researchers, scientists, and strategists.

The health consultancy has now expanded its US capabilities with the acquisition of Innovative Science Solutions (ISS). The New Jersey–based firm was founded in 2000, and provides advisory services to health and life sciences firms that span the entire product lifecycle – from development to post-market stewardship. The company has worked with pharmaceutical, medical device, chemical, cosmetics, food, and dietary supplement companies.

ISS bought by healthcare consultancy Cello Health

ISS specializes in strategic regulatory support and legal advisory, providing support across all stages of the regulatory process, advising on FDA Advisory Committee meetings, and providing data in legal defense of patent and IP issues.

Stephen Highley, chairman of Cello Health, said, "Consistent with Cello Health, ISS has achieved a strong reputation for provision of its scientific consulting services, and the specificity of these technical services is a perfect addition to Cello's focus on supporting client's along the most critical drug development and successful commercialization pathways."

The transaction will see ISS founders Steven Weisman, PhD and David Schwartz, PhD and their team join the growing Cello Health US operation.

"The acquisition of ISS is an excellent strategic fit as we continue our expansion in the US," Julia Ralston, CEO, Cello Health US, added. "We are excited about how the clear synergies between this new offer and our existing capabilities will benefit Cello Health's clients and our work tackling their biggest challenges in navigating scientific, commercial, and regulatory approaches that increase an asset's market potential."

Cello in 2017 acquired Defined Health, a New Jersey–based consultancy focused on early-stage biotechnology.